PAVELEK, Zbyšek, Oldřich VYŠATA, Lukáš SOBÍŠEK, Blanka KLÍMOVA, Ctirad ANDRÝS, Doris VOKURKOVÁ, Radka MAZUROVÁ, Pavel ŠTOURAČ and Martin VALIŠ. Lymphocyte populations and their change during five-year glatiramer acetate treatment. Neurologia i Neurochirurgia Polska. Poznan: Termedia Publishing House LTD, 2018, vol. 52, No 5, p. 587-592. ISSN 0028-3843. Available from: https://dx.doi.org/10.1016/j.pjnns.2018.08.001.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Lymphocyte populations and their change during five-year glatiramer acetate treatment
Authors PAVELEK, Zbyšek (203 Czech Republic, guarantor), Oldřich VYŠATA, Lukáš SOBÍŠEK (203 Czech Republic), Blanka KLÍMOVA (203 Czech Republic), Ctirad ANDRÝS (203 Czech Republic), Doris VOKURKOVÁ (203 Czech Republic), Radka MAZUROVÁ, Pavel ŠTOURAČ (203 Czech Republic, belonging to the institution) and Martin VALIŠ (203 Czech Republic).
Edition Neurologia i Neurochirurgia Polska, Poznan, Termedia Publishing House LTD, 2018, 0028-3843.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher Poland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 1.006
RIV identification code RIV/00216224:14110/18:00104209
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.pjnns.2018.08.001
UT WoS 000446401500007
Keywords in English Multiple sclerosis; Lymphocytes; Glatiramer acetate; Parameters; Treatment
Tags 14110221, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 15:46.
Abstract
Background: The goal of this study was to determine the characteristics that are affected in patients treated with glatiramer acetate (GA). Methods: A total of 113 patients were included in this study. Patients were treated with glatiramer acetate (subcutaneous injection, 20 mg, each day). Peripheral blood samples were obtained just prior to treatment as well as 5 years after GA treatment. All the calculations were performed with the statistical system R (r-project.org). Results: After 5 years of treatment, a significant decrease was found in the absolute and relative CD3+/CD69+ counts, the absolute and relative CD69 counts, the relative CD8+/CD38+ count and the relative CD38 count. A significant increase was found in the absolute and relative CD5+/CD45RA+ counts and the absolute CD5+/CD45RO+ count after 5 years of treatment. Conclusion: This study presents some parameters that were affected by long-term GA treatment. (C) 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
PrintDisplayed: 15/6/2024 20:25